Robert Kapito - IShares Pharmaceuticals Trustee

IHE Etf  USD 65.91  0.55  0.84%   
Robert Kapito is Portfolio Manager at iShares Pharmaceuticals ETF
Mr. Robert S. Kapito serves as Trustee of Ishares Dow Jones US Pharmaceuticals Index Fund since 2009. Mr. Kapito has served as a Director of iShares, Inc. since 2009, a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010 and a Director of BlackRock, Inc. since 2007. In addition, he has over 20 years of experience as part of BlackRock, Inc. and BlackRocks predecessor entities. Mr. Kapito serves as President and Director of BlackRock, Inc., and is the Chairman of the Operating Committee, a member of the Office of the Chairman, the Leadership Committee and the Corporationrationrate Council. He is responsible for daytoday oversight of BlackRocks key operating units, including the Account Management and Portfolio Management Groups, Real Estate Group and BlackRock Solutions. Prior to assuming his current responsibilities in 2007, Mr. Kapito served as Head of BlackRocks Portfolio Management Group. In that role, he was responsible for overseeing all portfolio management within BlackRock, including the Fixed Income, Equity, Liquidity, and Alternative Investment Groups. Mr. Kapito serves as a member of the Board of Trustees of the University of Pennsylvania. He is also President of the Board of Directors for the Hope Heroes Childrens Cancer Fund since 2002 and President of the Board of Directors for Periwinkle Theatre for Youth, a national nonprofit artsin education organization, since 1983
Age 62
Tenure 16 years
Professional MarksMBA
IssueriShares
Inception Date2006-05-01
BenchmarkDow Jones U.S. Select Pharmaceuticals Index
Entity TypeRegulated Investment Company
Asset Under Management610.64 Million
Average Trading Valume79,088
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets
Kapito earned a BS degree in economics from the Wharton School of the University of Pennsylvania in 1979, and an MBA degree from Harvard Business School in 1983.

Similar Fund Executives

Showing other executives

One Year Return

Madhav RajaniShares Insurance ETF
52
Chad HallettSPDR SP Pharmaceuticals
46
Kevin GustafsonInvesco Dynamic Pharmaceuticals
42
Charles HurtyiShares Healthcare ETF
72
Eilleen ClavereiShares Healthcare ETF
60
Scott ZoltowskiSPDR SP Pharmaceuticals
43
Ronn BaggeInvesco Dynamic Pharmaceuticals
54
John ClarkSPDR SP Pharmaceuticals
45
Mary ZevenSPDR SP Pharmaceuticals
51
Matthew FlahertySPDR SP Pharmaceuticals
41
Eilleen ClavereiShares Insurance ETF
60
Dave KellySPDR SP Pharmaceuticals
N/A
John MartineziShares Insurance ETF
55
Philip NussbaumInvesco Dynamic Pharmaceuticals
51
Frank NesvetSPDR SP Pharmaceuticals
68
Keith OvittInvesco Dynamic Pharmaceuticals
49
John KerriganiShares Insurance ETF
60
Cecilia HerbertiShares Insurance ETF
67
Madhav RajaniShares Healthcare ETF
52
Peter AmbrosiniSPDR SP Pharmaceuticals
68
Marc KoleInvesco Dynamic Pharmaceuticals
52
The fund generally will invest at least 80 percent of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. US Pharmaceuticals is traded on NYSEARCA Exchange in the United States. iShares Pharmaceuticals ETF [IHE] is traded in USA and was established 2006-05-01.

iShares Pharmaceuticals Money Managers

Geoffrey Flynn, Chief Operating Officer, Executive Vice President
Robert Silver, Independent Trustee
John Kerrigan, Independent Trustee
Madhav Rajan, Independent Trustee
Matt Tucker, Vice President
Cecilia Herbert, Independent Trustee
Michael Latham, President Trustee
Jack Gee, Chief Financial Officer, Treasurer
Charles Hurty, Independent Trustee
Eilleen Clavere, Secretary
George Parker, Independent Chairman of the Board of Trustees
John Martinez, Independent Trustee
Amy Schioldager, Executive Vice President
Robert Kapito, Trustee
Ira Shapiro, Vice President Chief Legal Officer

IShares Etf Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether iShares Pharmaceuticals is a strong investment it is important to analyze IShares Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact IShares Pharmaceuticals' future performance. For an informed investment choice regarding IShares Etf, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.